PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Vetter’s V-OVS® next Earns Prestigious Red Dot Design Concept Award

Novel syringe closure system honoured for its innovative design and enhanced user experience

  • Award recognises innovative design concept
  • New syringe closure system builds on more than two decades of market success

Vetter, a leading global Contract Development and Manufacturing Organisation (CDMO), has received a Red Dot Award in the category “Design Concept” for its next-generation syringe closure system, V-OVS® next. The internationally recognized award honours forward-looking product concepts distinguished by innovation, functionality and design excellence. The recognition highlights Vetter’s continued commitment to developing an advanced closure system that improves the user experience while supporting the evolving needs of pharma and biotech companies.

Developed in response to growing market complexity, particularly in biologics and user-oriented drug products, V-OVS® next represents the latest evolution of Vetter’s syringe closure technology. The system incorporates multiple design enhancements intended to improve safety, usability, and compatibility across a range of syringe formats, helping to establish a new standard for Luer Lock syringe closure systems.

“We are honored that V-OVS® next has been recognized with a Red Dot Award,” said Dr. Claus Feussner, Senior Vice President Development Service at Vetter. “This achievement reflects our commitment to combining technical innovation with meaningful user insights. Throughout development, we focused on creating a closure system that enhances functionality and patient safety, while delivering a more intuitive handling experience. Awards like this confirm that innovative pharmaceutical packaging must address both technical requirements and human factors to deliver meaningful value.”

One of the system’s key features is a robust locking mechanism designed to provide a secure connection between the syringe and the closure part, helping to reduce the risk of unintended rotation. V-OVS® next also incorporates a tamper-evident seal that irreversibly breaks upon first opening, offering an immediate visual indication of product status while supporting safety, product integrity, and user confidence.

In addition to its technical advancements, the closure system was specifically engineered with user-centric design principles. Ergonomic gripping elements help users intuitively identify handling points, while integrated visual opening indicators contribute to a straightforward opening process. The overall design combines functionality with a premium appearance, enabling pharma and biotech companies to further differentiate their therapies in an increasingly competitive marketplace.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC